Loading
Life sciences · Journal article
Journal of Endocrinological Investigation · August 12, 2026
A consensus or society position rather than new primary data.
This is a structured expert consensus on integrated management of overweight and obesity in Italy, reflecting current opinion on early pharmacological intervention and multi-risk-factor control. It does not provide empirical outcome data and represents professional guidance rather than clinical evidence of efficacy or harm.
Multicenter, multispecialty modified Delphi consensus study. Fifteen expert panelists in Italy with specified criteria to manage two patient subgroups: overweight (BMI 27–<30 kg/m²) with ≥1 weight-related comorbidity, and obesity (BMI ≥30 kg/m²).. Intervention: Modified Delphi consensus process on integrated obesity management strategies, early pharmacological intervention, and cardiovascular risk factor control.. n = 15. Italy.
93% agreement that typical patients have overweight or obesity combined with cardiovascular risk factors 100% consensus that early body-weight control may exert favourable long-term effect on cardiovascular risk and may decrease early mortality risk 100% consensus that early novel pharmacological treatment may decrease substantially cardiovascular event risk
Source does not report which novel pharmacological treatments were considered or strength of underlying evidence for claimed cardiovascular benefits. 100% consensus that early body-weight control may exert favourable long-term effect on cardiovascular risk and may decrease early mortality risk
This consensus supports early integrated management of overweight and obesity with attention to cardiovascular risk factors and novel pharmacological treatments. Clinicians should note that recommendations reflect expert opinion rather than trial-derived outcome data, and the borderline consensus (67%) on the 15% weight-loss target in obesity indicates less certainty on this specific metric.
A modified Delphi consensus study synthesizing expert opinion on integrated obesity management; provides recommendations but does not generate new empirical evidence on clinical outcomes.
As stated by the source record.
Quoted from the source exactly as published.
This consensus supports early integrated management of overweight and obesity with attention to cardiovascular risk factors and novel pharmacological treatments. Clinicians should note that recommendations reflect expert opinion rather than trial-derived outcome data, and the borderline consensus (67%) on the 15% weight-loss target in obesity indicates less certainty on this specific metric.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Purpose A comprehensive approach to the management of obesity, considering its complications besides the disease itself, may be advantageous, and effective obesity medications are now available. Several aspects of the integrated management of overweight/obesity are still unclear or are rapidly evolving. Methods We conducted a multicenter, multispecialty consensus based on the iterative modified Delphi methodology. The study ensured the fundamental principles of anonymity, iteration, controlled feedback, and statistical stability of the consensus. Management of two main patient subgroups was investigated, i.e., patients with overweight (body mass index, BMI 27-<30 kg/m 2 ) with ≥ 1 weight-related comorbidity, and patients with obesity (BMI ≥ 30 kg/m 2 ). Fifteen panelists had the required criteria and participated in the survey. Two Delphi rounds were required to complete the study, for a total of 93 items investigated. Results Almost all panelists (high consensus, 93% agreement) described their typical patient as one with overweight or obesity combined with other cardiovascular (CV) risk factors. Full consensus (100% agreement) emerged that early control of body weight in patients with overweight or obesity may exert a favorable long-term effect on CV risk and may decrease the risk of early mortality, and that early treatment with novel pharmacological treatments may decrease substantially the risk of CV events. The target for weight loss was agreed by the experts at 10% to 15% reduction in patients with overweight/comorbidities (full consensus, 100% agreement) and 15% reduction in patients with obesity (borderline consensus, 67% agreement). The panel recognized the improved control of multiple metabolic parameters (i.e., glycemia, blood pressure, lipids) among the main potential benefits of novel pharmacological treatments (full consensus, 100% agreement). Conclusions Broad agreement was found across several topics related to obesity management, including the recognized value of an early, effective pharmacological treatment to control overweight/obesity, and the relevance of addressing multiple CV risk factors in addition to reducing body weight.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.